EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression

Nikola Pavlović, Marinela Križanac, Marko Kumrić iD, Katarina Vukojević iD, Joško Božić iD

Cells · 28.05.2025 · 14 (11) · 794

DOI: 10.3390/cells14110794 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 28.05.2025. Verfasst von Nikola Pavlović und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Histology and Embryology, University of Split School of Medicine, 21000 Split, Croatia. Hauptthemen laut MEDLINE: Mitochondria, Disease Progression, Kidney Diseases. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Croatian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitochondrial dysfunction is a pivotal driver in the pathogenesis of acute kidney injury (AKI), chronic kidney disease (CKD), and congenital anomalies of the kidney and urinary tract (CAKUT). The kidneys, second only to the heart in mitochondrial density, rely on oxidative phosphorylation to meet the high ATP demands of solute reabsorption and filtration. Disrupted mitochondrial dynamics, such as excessive fission mediated by Drp1, exacerbate tubular apoptosis and inflammation in AKI models like ischemia–reperfusion injury. In CKD, persistent mitochondrial dysfunction drives oxidative stress, fibrosis, and metabolic reprogramming, with epigenetic mechanisms (DNA methylation, histone modifications, non-coding RNAs) regulating genes critical for mitochondrial homeostasis, such as PMPCB and TFAM. Epigenetic dysregulation also impacts mitochondrial–ER crosstalk, influencing calcium signaling and autophagy in renal pathology. Mitophagy, the selective clearance of damaged mitochondria, plays a dual role in kidney disease. While PINK1/Parkin-mediated mitophagy protects against cisplatin-induced AKI by preventing mitochondrial fragmentation and apoptosis, its dysregulation contributes to fibrosis and CKD progression. For instance, macrophage-specific loss of mitophagy regulators like MFN2 amplifies ROS production and fibrotic responses. Conversely, BNIP3/NIX-dependent mitophagy attenuates contrast-induced AKI by suppressing NLRP3 inflammasome activation. In diabetic nephropathy, impaired mitophagy correlates with declining eGFR and interstitial fibrosis, highlighting its diagnostic and therapeutic potential. Emerging therapeutic strategies target mitochondrial dysfunction through antioxidants (e.g., MitoQ, SS-31), mitophagy inducers (e.g., COPT nanoparticles), and mitochondrial transplantation, which mitigates AKI by restoring bioenergetics and modulating inflammatory pathways. Nanotechnology-enhanced drug delivery systems, such as curcumin-loaded nanoparticles, improve renal targeting and reduce oxidative stress. Epigenetic interventions, including PPAR-α agonists and KLF4 modulators, show promise in reversing metabolic reprogramming and fibrosis. These advances underscore mitochondria as central hubs in renal pathophysiology. Tailored interventions—ranging from Drp1 inhibition to mitochondrial transplantation—hold transformative potential to mitigate kidney injury and improve clinical outcomes. Additionally, dietary interventions and novel regulators such as adenogens are emerging as promising strategies to modulate mitochondrial function and attenuate kidney disease progression. Future research should address the gaps in understanding the role of mitophagy in CAKUT and optimize targeted delivery systems for precision therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaDisease ProgressionKidney DiseasesHumansAnimalsMitophagyMitochondrial DynamicsRenal Insufficiency, Chronic

Stichwörter der Autor:innen

CAKUTacute kidney injurychronic kidney diseasemitochondriamitophagyrenal pathology

Autor:innen und Institutionen

  • Department of Anatomy, Histology and Embryology, University of Split School of Medicine, 21000 Split, Croatia.
  • Department of Paediatrics, University Hospital of Split, 21000 Split, Croatia.
  • Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.
  • Laboratory for Cardiometabolic Research, University of Split School of Medicine, 21000 Split, Croatia.
  • Mediterranean Institute for Life Sciences, University of Split, 21000 Split, Croatia.
  • Center for Translational Research in Biomedicine, University of Split School of Medicine, 21000 Split, Croatia.

ORCID-Profile: Marko Kumrić, Katarina Vukojević, Joško Božić

Förderung

  • Croatian Science Foundation

Zitieren

APA

Pavlović, N., Križanac, M., Kumrić, M., Vukojević, K., & Božić, J. (2025). Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression. Cells, 14(11), 794. https://doi.org/10.3390/cells14110794

Vancouver

Pavlović N, Križanac M, Kumrić M, Vukojević K, Božić J. Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression. Cells. 2025;14(11):794. doi:10.3390/cells14110794

BibTeX
@article{Pavlovi2025,
  author = {Pavlović, Nikola and Križanac, Marinela and Kumrić, Marko and Vukojević, Katarina and Božić, Joško},
  title = {Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {11},
  pages = {794},
  doi = {10.3390/cells14110794}
}
Kostenlos starten →